DK1206189T3 - Rotavirusvaccineformuleringer - Google Patents
RotavirusvaccineformuleringerInfo
- Publication number
- DK1206189T3 DK1206189T3 DK00955357T DK00955357T DK1206189T3 DK 1206189 T3 DK1206189 T3 DK 1206189T3 DK 00955357 T DK00955357 T DK 00955357T DK 00955357 T DK00955357 T DK 00955357T DK 1206189 T3 DK1206189 T3 DK 1206189T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulations
- vaccine formulations
- rotavirus vaccine
- rotavirus
- vaccines
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 229940124859 Rotavirus vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000702670 Rotavirus Species 0.000 abstract 1
- 206010067470 Rotavirus infection Diseases 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/366,616 US6403098B1 (en) | 1996-09-26 | 1999-08-03 | Rotavirus vaccine formulations |
PCT/US2000/021264 WO2001008495A1 (en) | 1999-08-03 | 2000-08-03 | Rotavirus vaccine formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1206189T3 true DK1206189T3 (da) | 2005-08-29 |
Family
ID=23443770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00955357T DK1206189T3 (da) | 1999-08-03 | 2000-08-03 | Rotavirusvaccineformuleringer |
Country Status (11)
Country | Link |
---|---|
US (1) | US6403098B1 (es) |
EP (1) | EP1206189B1 (es) |
JP (1) | JP4138314B2 (es) |
AT (1) | ATE296538T1 (es) |
AU (1) | AU6757600A (es) |
CA (1) | CA2378864A1 (es) |
DE (1) | DE60020570T2 (es) |
DK (1) | DK1206189T3 (es) |
ES (1) | ES2240145T3 (es) |
PT (1) | PT1206189E (es) |
WO (1) | WO2001008495A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616931B1 (en) * | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
DE122006000026I1 (de) * | 1999-08-17 | 2006-10-12 | Glaxosmithkline Biolog Sa | Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
EP1327450B1 (de) * | 2002-01-15 | 2007-08-15 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | Orale Vakzinierung mit nackten Tumor-Antigen-Mimotopen |
ATE361097T1 (de) * | 2002-01-15 | 2007-05-15 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp |
WO2005099751A2 (en) | 2004-04-01 | 2005-10-27 | Alza Corporation | Apparatus and method for transdermal delivery of influenza vaccine |
GB0503337D0 (en) * | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
WO2007081447A2 (en) | 2005-11-22 | 2007-07-19 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
US20100056825A1 (en) * | 2008-08-28 | 2010-03-04 | Telik, Inc. | Formulations of canfosfamide and their preparation |
US8324426B2 (en) * | 2008-08-28 | 2012-12-04 | Telik, Inc. | Formulations of canfosfamide and their preparation |
CN102202688B (zh) * | 2008-11-07 | 2017-04-12 | 印度血清研究所私人有限公司 | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 |
WO2012075379A2 (en) | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
AU2011336410B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Lyophilized viral formulations |
JP5798356B2 (ja) * | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
HUE035774T2 (en) | 2011-08-12 | 2018-05-28 | Merial Inc | Biological substances, in particular vaccines, preserved by vacuum |
WO2013029033A2 (en) * | 2011-08-25 | 2013-02-28 | Brian Pulliam | Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures |
CN110227152A (zh) | 2012-04-23 | 2019-09-13 | 巴拉特生物技术国际有限公司 | 轮状病毒疫苗组合物及其制备方法 |
US9480739B2 (en) * | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
US10532093B2 (en) * | 2014-07-18 | 2020-01-14 | Mds Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof |
US10556000B2 (en) * | 2014-07-18 | 2020-02-11 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Thermostable spray dried rotavirus vaccine formulation and process thereof |
MA44557B1 (fr) | 2016-06-16 | 2021-11-30 | Bharat Biotech Int Ltd | Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer |
PL3522871T3 (pl) * | 2016-10-05 | 2022-02-14 | Zoetis Services Llc | Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki |
US11110163B2 (en) | 2017-02-14 | 2021-09-07 | Inventprise, Llc | Heat stable vaccines |
US10413604B2 (en) | 2017-02-14 | 2019-09-17 | Inventprise, Llc | Heat stable liquid rotavirus vaccine |
CN111150849A (zh) * | 2020-04-02 | 2020-05-15 | 广州隽沐生物科技股份有限公司 | 一种组合物及其制备方法及其应用 |
CN114392237B (zh) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | 一种冻干病毒制剂及其制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT71926B (en) * | 1979-10-29 | 1982-03-31 | Merck & Co Inc | Process for preparing a liquid vaccine comprising a stabilizer |
FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
US4636385A (en) | 1985-02-15 | 1987-01-13 | The Wistar Institute Of Anatomy & Biology | Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection |
US5626851A (en) | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
WO1996001651A1 (en) | 1994-07-11 | 1996-01-25 | The Government Of The United States Of America, Represented By The Department Of Health And Human Services | Attenuated human rotavirus vaccine |
EP1181937A3 (en) * | 1994-08-09 | 2004-02-04 | Cytrx Corporation | Novel vaccine adjuvant and vaccine |
US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
ES2294801T3 (es) * | 1996-09-26 | 2008-04-01 | MERCK & CO., INC. | Formulaciones de vacunas contra rotavirus. |
US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
-
1999
- 1999-08-03 US US09/366,616 patent/US6403098B1/en not_active Expired - Lifetime
-
2000
- 2000-08-02 AU AU67576/00A patent/AU6757600A/en not_active Abandoned
- 2000-08-03 DE DE60020570T patent/DE60020570T2/de not_active Expired - Lifetime
- 2000-08-03 JP JP2001513242A patent/JP4138314B2/ja not_active Expired - Fee Related
- 2000-08-03 EP EP00955357A patent/EP1206189B1/en not_active Expired - Lifetime
- 2000-08-03 DK DK00955357T patent/DK1206189T3/da active
- 2000-08-03 PT PT00955357T patent/PT1206189E/pt unknown
- 2000-08-03 AT AT00955357T patent/ATE296538T1/de active
- 2000-08-03 CA CA002378864A patent/CA2378864A1/en not_active Abandoned
- 2000-08-03 WO PCT/US2000/021264 patent/WO2001008495A1/en active IP Right Grant
- 2000-08-03 ES ES00955357T patent/ES2240145T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2001008495A1 (en) | 2001-02-08 |
EP1206189A4 (en) | 2003-03-12 |
JP4138314B2 (ja) | 2008-08-27 |
US6403098B1 (en) | 2002-06-11 |
AU6757600A (en) | 2001-02-19 |
ES2240145T3 (es) | 2005-10-16 |
ATE296538T1 (de) | 2005-06-15 |
DE60020570T2 (de) | 2006-05-04 |
JP2003505482A (ja) | 2003-02-12 |
EP1206189B1 (en) | 2005-06-01 |
PT1206189E (pt) | 2005-09-30 |
DE60020570D1 (de) | 2005-07-07 |
EP1206189A1 (en) | 2002-05-22 |
CA2378864A1 (en) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60020570D1 (de) | Rotavirus impfstoffformulierungen | |
MY129263A (en) | Vaccine composition | |
HUP0101619A2 (hu) | Adjuvánskészítmények | |
PT1412384E (pt) | Formulação estável de glp-1 modificado | |
DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
SE8804629D0 (sv) | New therapeutically active compounds | |
DK1299348T3 (da) | Forbindelser og sammensætninger til levering af aktive midler | |
FR2762843B1 (fr) | Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent | |
EE05089B1 (et) | Amiidasendatud imidasokinoliinid ja neid sisaldavad farmatseutilised preparaadid | |
MXPA03005464A (es) | Agentes antivirales. | |
MXPA02006029A (es) | Lipopeptidos novedosos como agentes antibacterianos. | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
HK1076605A1 (en) | Formulations | |
MXPA02006030A (es) | Lipopeptidos como agentes antibacterianos. | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
HUP0301349A2 (hu) | IL-11-tartalmú készítmények | |
MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
AU2002221519A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
DK1057828T3 (da) | Orale trovafloxacin-suspensioner | |
EE200200252A (et) | Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks | |
AP9801235A0 (en) | Erythromycin derivatives. | |
YU24603A (sh) | Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin | |
FR2809961B1 (fr) | Utilisation d'ethers de sucres, comme adjuvants d'immunite dans les compositions vaccinales, compositions therapeutiques les renfermant et leur utilisation comme vaccins | |
IL150979A0 (en) | 9-alkylamino-1-nitroacridine derivatives | |
IT1317836B1 (it) | Uso del tiamfenicolo per la preparazione di composizioni farmaceuticheutili per il trattamento di infezioni da staphylococci |